Wendy Stock
#156,321
Most Influential Person Now
Researcher
Wendy Stock's AcademicInfluence.com Rankings
Wendy Stockeconomics Degrees
Economics
#3380
World Rank
#3831
Historical Rank
Macroeconomics
#304
World Rank
#320
Historical Rank
Download Badge
Economics
Why Is Wendy Stock Influential?
(Suggest an Edit or Addition)Wendy Stock's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. (2006) (1186)
- Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. (2014) (1029)
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. (2016) (882)
- The genomic landscape of hypodiploid acute lymphoblastic leukemia (2013) (585)
- TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. (2016) (582)
- Gene expression changes associated with progression and response in chronic myeloid leukemia. (2006) (570)
- What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. (2008) (487)
- Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. (2010) (349)
- High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. (2017) (281)
- PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia (2019) (274)
- MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. (2014) (258)
- Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. (1993) (253)
- International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data. (2022) (249)
- A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. (2019) (239)
- A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. (2006) (231)
- Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. (2015) (230)
- A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies (2008) (225)
- Adult acute lymphoblastic leukemia (2010) (198)
- Deregulation of DUX4 and ERG in acute lymphoblastic leukemia (2016) (197)
- Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel (2011) (192)
- Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. (2009) (189)
- Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients (2014) (188)
- Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia (2016) (181)
- Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study (2019) (176)
- High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. (2013) (169)
- A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. (2012) (163)
- Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. (2011) (156)
- Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. (2005) (142)
- Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. (2002) (140)
- In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. (2015) (139)
- Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. (2005) (134)
- Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis (1996) (126)
- Adolescents and young adults with acute lymphoblastic leukemia. (2010) (123)
- Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. (2006) (120)
- Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. (2017) (118)
- P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. (2010) (111)
- Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia (2013) (109)
- Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial (2013) (105)
- Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of U.S. Intergroup Trial C10403 (2014) (105)
- How I treat acute lymphoblastic leukemia in older adolescents and young adults. (2015) (105)
- A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma (2015) (98)
- Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. (2017) (97)
- Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients (2015) (96)
- A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. (2014) (95)
- Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). (2009) (94)
- Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL. (2017) (93)
- Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease (2000) (90)
- Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance) (2014) (90)
- Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia (2016) (88)
- Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study. (2020) (87)
- Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: A Review (2018) (86)
- Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS (2018) (83)
- Management of important adverse events associated with inotuzumab ozogamicin: expert panel review (2018) (80)
- BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants. (2009) (80)
- Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. (2021) (78)
- Brusatol-mediated induction of leukemic cell differentiation and G1 arrest is associated with down-regulation of c-myc (2002) (77)
- NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, (2010) (76)
- Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation (2007) (75)
- Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. (2008) (73)
- A Phase I Biological Study of MG98, an Oligodeoxynucleotide Antisense to DNA Methyltransferase 1, in Patients with High-Risk Myelodysplasia and Acute Myeloid Leukemia (2008) (72)
- Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909 (2012) (71)
- Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial (2020) (67)
- Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia (2008) (67)
- Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102). (2009) (66)
- A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. (2006) (65)
- Paucity of HLA-identical unrelated donors for African-Americans with hematologic malignancies: the need for new donor options. (2008) (62)
- Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. (2019) (62)
- Interpersonal Violence and Posttraumatic Symptomatology (2000) (61)
- Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome (2021) (60)
- White blood cells 1: non-malignant disorders (2000) (60)
- Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype (2014) (60)
- Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL (2016) (60)
- A phase III randomized trial of intensive induction and consolidation chemotherapy ± oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old (2007) (60)
- Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. (2012) (59)
- Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval. (1996) (59)
- Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance) (2013) (59)
- Adolescents and Young Adults with Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia: Impact of Care at Specialized Cancer Centers on Survival Outcome (2017) (59)
- Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia (2014) (59)
- Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence (2009) (58)
- Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B study (CALGB 10503) (2016) (56)
- Psychological morbidities in adolescent and young adult blood cancer patients during curative‐intent therapy and early survivorship (2016) (56)
- Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia (2014) (55)
- Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. (2019) (53)
- Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes (2005) (53)
- A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. (2017) (53)
- Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia (2009) (53)
- Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia (2017) (52)
- Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. (2009) (52)
- Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia. (2019) (50)
- An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine‐Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia (2017) (50)
- Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia (2008) (49)
- A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia (2018) (49)
- Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia (2021) (47)
- Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning (2006) (47)
- Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. (2012) (47)
- Regimen-related toxicity after fludarabine–melphalan conditioning: a prospective study of 31 patients with hematologic malignancies (2003) (46)
- FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: A report from the Children's Oncology Group (2012) (45)
- Progress in the treatment of adults with acute lymphoblastic leukemia (2008) (44)
- Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. (2004) (43)
- Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO‐VATE (2018) (43)
- Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study (2018) (43)
- Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia (2012) (42)
- Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665 (2016) (42)
- Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. (2019) (41)
- Adding KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-Expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB 10801 (Alliance) (2014) (40)
- Allogeneic and autologous transplantation for chronic lymphocytic leukemia (2001) (40)
- Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with Newly Diagnosed Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia (2018) (40)
- Treatment of Acute Promyelocytic Leukemia in Adults. (2018) (39)
- Umbilical cord blood transplantation supported by third-party donor cells: rationale, results, and applications. (2013) (39)
- Cell cycle regulatory gene abnormalities are important determinants of leukemogenesis and disease biology in adult acute lymphoblastic leukemia. (2000) (37)
- Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study. (2019) (37)
- Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy (2014) (36)
- Daunorubicin Dose Intensification during Treatment of Adult Acute Lymphoblastic Leukemia (ALL): Final Results from Cancer and Leukemia Group B Study 19802. (2005) (36)
- Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant (2001) (35)
- Next generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma (2015) (35)
- Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion. (2001) (34)
- Phase II Trial of Low Dose, Subcutaneous Decitabine in Myelofibrosis (2008) (34)
- Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study (2020) (34)
- Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance). (2020) (34)
- Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen (2018) (34)
- Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL. (2019) (34)
- Studies of minimal residual disease in acute lymphocytic leukemia. (2000) (33)
- NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic (2010) (33)
- A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia (2009) (33)
- Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia (2020) (33)
- Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia (2016) (33)
- A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804 (2009) (32)
- Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. (2020) (32)
- Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. (2012) (32)
- First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML) (2013) (32)
- Adoption of pediatric‐inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population‐based study (2017) (32)
- Minimal Residual Disease in Acute Myeloid Leukemia—Current Status and Future Perspectives (2015) (31)
- A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results (2019) (31)
- Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403 (2015) (31)
- A Randomized Phase II Trial of Dasatinib 100 Mg Vs Imatinib 400 Mg In Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): The S0325 Intergroup Trial (2010) (30)
- Adding The KIT Inhibitor Dasatinib (DAS) To Standard Induction and Consolidation Therapy For Newly Diagnosed Patients (pts) With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Initial Results Of The CALGB 10801 (Alliance) Study (2013) (30)
- High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. (2011) (30)
- Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease (2010) (30)
- Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (2019) (29)
- Enhancer hijacking drives oncogenic BCL11B expression in lineage ambiguous stem cell leukemia. (2021) (29)
- Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival (2016) (29)
- Concepts and Strategies (2010) (29)
- Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia. (2019) (29)
- Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples. (2006) (28)
- Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). (2018) (28)
- REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia (2014) (28)
- Value of molecular monitoring during the treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B study. (1997) (28)
- Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia (2020) (27)
- Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. (2019) (27)
- Management of adult acute lymphoblastic leukemia: moving toward a risk-adapted approach. (2001) (26)
- Recombinant interleukin‐2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808 (2013) (26)
- A Randomized Comparison of Induction Therapy for Untreated Acute Myeloid Leukemia (AML) in Patients < 60 Years Using P-Glycoprotein (Pgp) Modulation with Valspodar (PSC833): Preliminary Results of Cancer and Leukemia Group B Study 19808. (2005) (25)
- Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden (2020) (25)
- Immune reconstitution after combined haploidentical and umbilical cord blood transplant (2013) (25)
- Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet? (2011) (25)
- Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia. (2020) (24)
- A Phase II Study of Weekly Inotuzumab Ozogamicin (InO) in Adult Patients with CD22-Positive Acute Lymphoblastic Leukemia (ALL) in Second or Later Salvage (2014) (24)
- Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML (2010) (24)
- Clinical outcomes of IDH2‐mutated advanced‐phase Ph‐negative myeloproliferative neoplasms treated with enasidenib (2020) (24)
- Weekly Inotuzumab Ozogamicin (InO) In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL) (2012) (24)
- Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. (2019) (24)
- Treatment of young adults with Philadelphia‐negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper‐CVAD vs. pediatric‐inspired regimens (2018) (23)
- High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk Acute Myeloid Leukemia (AML) (2012) (22)
- Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (2010) (22)
- Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia (2020) (21)
- Impact of Treatment Site on Disparities in Outcome among Adolescent and Young Adults with Hodgkin Lymphoma (2017) (21)
- Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia (2017) (21)
- Certain HLA antigens are associated with specific morphologic and cytogenetic subsets of acute myeloid leukemia. (1995) (21)
- Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. (2020) (21)
- Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR (2021) (20)
- Burkitt lymphoma/leukemia: improving prognosis. (2009) (20)
- Results From the Dose Escalation Phase of a Randomized Phase 1–2 First-in-Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapsed/Refractory MDS and AML (2012) (20)
- A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes (2013) (20)
- Incorporation of Alemtuzumab into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL) Is Feasible: A Phase I/II Study from the Cancer and Leukemia Group B (CALGB 10102). (2005) (20)
- An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. (2011) (20)
- T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia (2015) (20)
- Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. (2019) (20)
- Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes (2022) (19)
- Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia. (2018) (19)
- Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. (2016) (18)
- Targeting Suppressor of Variegation 3-9 Homologue 2 (SUV39H2) in Acute Lymphoblastic Leukemia (ALL)1 (2015) (18)
- Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant (2014) (18)
- Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. (2017) (17)
- Inclusion of Adolescents and Young Adults in Cancer Clinical Trials. (2015) (17)
- Stem cell transplantation eliminates alloantibody in a highly sensitized patient. (2001) (17)
- Corrigendum: Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia (Leukemia (2016) 30 (1672-1681) DOI: 10.1038/leu.2016.69) (2016) (17)
- T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse (2011) (17)
- Diagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL) (2017) (17)
- Unrelated donor transplantation over the age of 55. Are we merely getting (b)older? (2005) (17)
- Children, adolescents, and young adults with leukemia: the empty half of the glass is growing. (2012) (17)
- Barriers to Hematopoietic Cell Transplantation for Adults in the United States: A Systematic Review with a Focus on Age. (2020) (16)
- Biology and Treatment Paradigms in T Cell Acute Lymphoblastic Leukemia in Older Adolescents and Adults (2020) (16)
- Enasidenib Is Highly Active in Previously Untreated IDH2 Mutant AML: Early Results from the Beat AML Master Trial (2018) (16)
- Detection of MLL gene rearrangements in adult acute lymphoblastic leukemia. A Cancer and Leukemia Group B study. (1994) (16)
- Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant (2010) (16)
- Hematopoietic Cell Transplantation Second Edition (1998) (15)
- Listeriosis after 2-chlorodeoxyadenosine treatment. (1993) (15)
- Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir (2003) (15)
- Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403 (2020) (15)
- Treatment decision-making in acute myeloid leukemia: a qualitative study of older adults and community oncologists (2020) (15)
- Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature (2021) (15)
- Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia. (2019) (15)
- Genomic aberrations in myeloid sarcoma without blood or bone marrow involvement: characterization of formalin-fixed paraffin-embedded samples by chromosomal microarrays. (2014) (15)
- Treatment of the Chronic Phase of Chronic Myeloid Leukemia with an Intermittent Schedule of Recombinant Interferon Alfa-2b and Cytarabine: Results from CALGB Study 9013 (2003) (14)
- Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing (2019) (14)
- Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia (2012) (14)
- Phase I study of belinostat (PXD101) plus azacitidine (AZC) in patients with advanced myeloid neoplasms (2008) (14)
- Influence of related donor age on outcomes after peripheral blood stem cell transplantation. (2012) (14)
- SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia (2022) (14)
- Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. (2021) (14)
- Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia. (2015) (14)
- WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia (2018) (14)
- Unexpected toxicities when nivolumab was given as maintenance therapy following allogeneic stem cell transplantation: Toxicities with maintenance nivolumab after allogeneic stem cell transplantation. (2020) (14)
- Adding Mercaptopurine and Methotrexate to Alternate Week ATRA Maintenance Therapy Does Not Improve the Outcome for Adults with Acute Promyelocytic Leukemia (APL) in First Remission: Results From North American Leukemia Intergroup Trial C9710 (2011) (13)
- Long Term Survival and Clinical Complete Responses of Various Prognostic Subgroups in 103 Relapsed/Refractory Acute Myeloid Leukemia (r/r AML) Patients Treated with Guadecitabine (SGI-110) in Phase 2 Studies (2016) (13)
- Progressive Transformation of Germinal Centers (2002) (13)
- Assaying Bcr-Abl kinase activity and inhibition in whole cell extracts by phosphorylation of substrates immobilized on agarose beads. (2005) (13)
- Successful allogeneic transplantation of patients with suspected prior invasive mold infection (2007) (13)
- Structural Racism is a Mediator of Disparities in Acute Myeloid Leukemia Outcomes. (2022) (12)
- Intergroup Trial C10403: A Pediatric Treatment Approach to Improve Outcomes in Adolescents and Young Adults with Acute Lymphoblastic Leukemia. (2011) (12)
- Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products (2008) (12)
- Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance) (2018) (12)
- High incidence of FLT3 mutations in adults with Acute Promyelocytic Leukemia (APL): Correlation with diagnostic features and treatment outcome (CALGB 9710) (2008) (12)
- Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma. (2004) (12)
- Progress in adult ALL: incorporation of new agents to frontline treatment. (2017) (12)
- Pembrolizumab for the treatment of disease relapse following allogeneic hematopoietic stem cell transplantation. (2018) (12)
- A phase II trial of interleukin‐2 in myelodysplastic syndromes (1998) (12)
- Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant (2019) (12)
- Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia (2009) (12)
- A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Transplantation for Adults with Newly Diagnosed Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Final Results of Alliance/CALGB Study 10701 (2018) (12)
- Refractory Hypokalemia from Syndrome of Apparent Mineralocorticoid Excess on Low-Dose Posaconazole (2018) (12)
- Initial Report of the Beat AML Umbrella Study for Previously Untreated AML: Evidence of Feasibility and Early Success in Molecularly Driven Phase 1 and 2 Studies (2018) (12)
- Integrated Genomic and Mutational Profiling Of Adolescent and Young Adult ALL Identifies a High Frequency Of BCR-ABL1-Like ALL with Very Poor Outcome (2013) (11)
- A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, in Elderly Patients with AML Previously Untreated or in First Relapse. (2009) (11)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
- Preliminary Results from the North American Acute Promyelocytic Leukemia (APL) Study C9710. (2006) (11)
- Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (2021) (11)
- Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012) (2009) (11)
- Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance) (2012) (11)
- Safety and outcome after fludarabine–thiotepa–TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies (2003) (10)
- Outcomes with inotuzumab ozogamicin (InO) in patients with Philadelphia chromosome–positive (Ph+) relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). (2018) (10)
- A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia (2015) (10)
- Expanded indications for allogeneic stem cell transplantation in patients with myeloid malignancies. (2013) (10)
- De Novo Development of Bronchiectasis in Patients With Hematologic Malignancy. (2017) (10)
- Impact of Care at NCI Comprehensive Cancer Centers (NCICCC) on Outcomes in Children, Adolescents and Young Adults (AYA) with Hematologic Malignancies (2014) (10)
- Feasibility of geriatric assessment for older adults with acute myeloid leukemia (AML) receiving intensive chemotherapy on a cooperative group trial: CALGB 361006 (Alliance). (2014) (10)
- Results from an Ongoing Phase 1 Study Indicate ACDT-301 (Camidanlumab Tesirine) Is Well-Tolerated in Patients with Relapsed or Refractory CD25-Positive Acute Leukemia (2017) (10)
- Characterization of yeast artificial chromosomes containing interleukin genes on human chromosome 5. (1992) (10)
- The Histone Deacetylase Inhibitor Depsipeptide Has Differential Activity in Specific Cytogenetic Subsets of Acute Myeloid Leukemia (AML). (2004) (10)
- The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13. (2021) (10)
- Interim Data from a Phase 1 Study Evaluating Pyrrolobenzodiazepine-Based Antibody Drug Conjugate ADCT-402 (Loncastuximab Tesirine) Targeting CD19 for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (2017) (10)
- CD5+, CD11c+, CD20+ hairy cell leukemia [letter; comment] (1991) (9)
- First Clinical Results of a Randomized Phase 2 Dose-Response Study of SGI-110, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate (Int) or High Risk (HR) Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) (2014) (9)
- Comparison of Efficacy and Safety Results in 103 Treatment-Naïve Acute Myeloid Leukemia (TN-AML) Patients Not Candidates for Intensive Chemotherapy Using 5-Day and 10-Day Regimens of Guadecitabine (SGI-110), a Novel Hypomethylating Agent (HMA) (2015) (9)
- Management of acute lymphoblastic leukemia in young adults. (2018) (9)
- Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin (2019) (9)
- A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia (2008) (9)
- Phase II Study of the Oral MEK Inhibitor AZD6244 in Advanced Acute Myeloid Leukemia (AML). (2009) (9)
- High Frequency and Poor Outcome of Ph-like Acute Lymphoblastic Leukemia in Adults (2015) (9)
- Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22 (2021) (9)
- Chimerism does not predict for outcome after alemtuzumab based conditioning (2007) (9)
- Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). (2021) (9)
- Reduced intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engrafment and durable remissions. (2011) (9)
- Phase 1 Results of ZUMA-3: KTE-C19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) (2017) (8)
- Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) (Alliance C11001) (2015) (8)
- Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials (2021) (8)
- A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469. (2014) (8)
- Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival (2020) (8)
- Abstract LB-214: Interim results from a randomized Phase 1-2 first-in-human (FIH) study of PK/PD guided escalating doses of SGI-110, a novel subcutaneous (SQ) second generation hypomethylating agent (HMA) in relapsed/refractory MDS and AML (2012) (8)
- Erratum: Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia (2016) (8)
- Acute lymphoblastic leukemia displays a distinct highly methylated genome (2022) (8)
- Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation: Final Report of a Phase I-II Study (2011) (8)
- A Phase I Study of Talvesta® (Talotrexin) in Relapsed or Refractory Leukemia or Myelodysplastic Syndrome. (2006) (8)
- Phase II study of marqibo in adult patients with refractory or relapsed philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL). (2010) (8)
- Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia. (2022) (8)
- RCSD1–ABL2 fusion resulting from a complex chromosomal rearrangement in high-risk B-cell acute lymphoblastic leukemia (2015) (8)
- Posttransplant Immunotherapy with a GM-CSF-Based Tumor Vaccine (GVAX®) Following Autologous Stem Cell Transplant (ASCT) for Acute Myeloid Leukemia (AML). (2004) (8)
- Incorporating measurable (‘minimal’) residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia (2016) (8)
- Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells. (2021) (7)
- Precision Medicine Treatment in Older AML: Results of Beat AML Master Trial (2019) (7)
- Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database (2020) (7)
- Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment (2016) (7)
- Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab (CMA) Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Advanced Hematologic Malignancies: Determination of MTD and Outcomes. (2009) (7)
- SOHO State of the Art Updates and Next Questions: Management of Asparaginase Toxicity in Adolescents and Young Adults with Acute Lymphoblastic Leukemia. (2021) (7)
- Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection. (2004) (7)
- FLT 3 Mutation Status is a Predictor of Early Death in Pediatric Acute Promyelocytic Leukemia : A Report From The Children ' s Oncology Group (7)
- Marqibo® (vincristine sulfate liposomes injection; VSLI) In the Treatment of Adult Patients with Advanced, Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL): A Combined Analysis of the VSLI-06 and RALLY Studies (2010) (7)
- Haplo-Cord Transplantation Vs Unrelated Donor Stem Cell Transplantation in Patients with AML/MDS Older Than 50 (2014) (7)
- Vaccine-associated immune and WT-1 responses are associated with better relapse-free survival in patients with AML in remission treated with a GM-CSF secreting leukemia vaccine and autologous stem cell transplant (ASCT) (2005) (6)
- Controversies in treatment of AML: case-based discussion. (2006) (6)
- A Dose Escalation and Phase II Study of Gemtuzumab Ozogamicin (GO) with High-Dose Cytarabine (HiDAC) for Patients (pts) with Refractory or Relapsed Acute Myeloid Leukemia (AML): CALGB 19902. (2004) (6)
- Phase II study of the oral MEK inhibitor selumetinib (AZD6244) in advanced acute myeloid leukemia (AML). (2012) (6)
- Inotuzumab ozogamicin (InO) for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) in the phase III INO-VATE trial: Efficacy and safety by prior therapy. (2016) (6)
- Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician (2018) (6)
- The Histone Deacetylase Inhibitor (HDI) Depsipeptide Has Differential Activity in Core Binding Factor AML. (2006) (6)
- Impact of gender and caregiving responsibilities on academic success in hematology. (2020) (6)
- Inotuzumab Ozogamicin (InO) Vs Standard of Care (SC) in Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Long-Term Results of the Phase 3 INO-VATE Study (2017) (6)
- First results of a phase 2 study using a 10-day subcutaneous (SC) regimen of the novel hypomethylating agent (HMA) SGI-110 for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML). (2014) (6)
- Clinical Predictors of Transplant Related Mortality after Reduced Intensity Allogeneic Stem Cell Transplantation (RIST). (2004) (6)
- Features of Frailty Are Surprisingly Common in Adults 50 Years and Older Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) in the Modern Era (2011) (6)
- TCR Clonal Evolution in AML Patients in Morphologic Remission Treated with Anti-PD1 Antibody, Nivolumab (2016) (6)
- A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Hematopoietic Cell Transplantation for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: CALGB Study 10701 (Alliance) (2016) (6)
- Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): 8 Year Follow up of CALGB 50403 (Alliance) (2018) (6)
- Distinct genetic pathways define pre-leukemic and compensatory clonal hematopoiesis in Shwachman-Diamond syndrome (2020) (6)
- Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia with Excess of Blasts in Transformation (RAEB-T) Enrolled in a Phase 3 Study of CPX-351 Versus Conventional 7 + 3 Cytarabine and Daunorubicin (2018) (6)
- The Persistence of Minimal Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: We Know It's Bad, Now What? (2016) (5)
- Haplo-Cord UCB SCT with Low Cell Dose, Well Matched UCB Units. a Prospective Multicenter Study (2014) (5)
- Impact of minimal residual disease (MRD) status in clinical outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial. (2018) (5)
- Phase II Study of Decitabine in Myelofibrosis with Myeloid Metaplasia. (2006) (5)
- Autologous Stem Cell Transplantation (SCT) Following Sequential Chemotherapy and Imatinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) — CALGB Study 10001. (2007) (5)
- Autologous Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Achieves Outcomes Similar to Allogeneic Transplantation - Results of CALGB 10001 (Alliance) (2012) (5)
- Marqibo®, Vincristine Sulfate Liposome Injection, for the Treatment of Advanced, Relapsed or Refractory Philadelphia Chromosome-Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) in an Adolescent Young Adult (AYA) Population (2015) (5)
- "Dar"-ing to target CD38 in T-ALL. (2018) (5)
- Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) (2018) (5)
- Quantitative Measurement of CD52 Expression and Alemtuzumab Binding in Adult Acute Lymphoblastic Leukemia (ALL): Correlation with Immunophenotype and Cytogenetics in Patients (Pts) Enrolled on a Phase I/II Trial from the Cancer and Leukemia Group B (CALGB 10102). (2007) (5)
- Initial Results Of a Phase II Trial Of Sorafenib Plus Standard Induction In Older Adults With Mutant FLT3 Acute Myeloid Leukemia (AML) (Alliance trial C11001) (2013) (5)
- Treating the younger adult with acute lymphoblastic leukemia (2012) (5)
- Venetoclax and Navitoclax in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (2018) (5)
- Comparison of CD22 Expression between Baseline, End of Treatment, and Relapse Among Patients Treated with Inotuzumab Ozogamicin Who Responded and Subsequently Relapsed in Two Clinical Trials (2018) (5)
- Allogeneic Hematopoietic Cell Transplantation From Combined Haploidentical Family Members and Unrelated Cord Blood (CB) Can Benefit High Risk Patients Lacking HLA-Identical Donors. (2009) (5)
- Combination of a MEK Inhibitor, AZD6244, and Dual PI3K/mTOR Inhibitor, NVP-BEZ235: An Effective Therapeutic Strategy for Acute Myeloid Leukemia (2010) (5)
- Advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. (2008) (5)
- Efficacy and safety of inotuzumab ozogamicin (InO) in older patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) enrolled in the phase 3 INO-VATE trial. (2016) (5)
- Early Signs of Tolerability and Activity in a Phase 2 Study of Weekly Vincristine Sulfate Liposomal Injection (VSLI, MarqiboÒ) in Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Progressing Following Two Anti-Leukemia Treatment Lines (2008) (5)
- Analysis of Minimal Residual Disease (MRD) from the Phase 2 Multicenter Study of Subcutaneous (SC) Alemtuzumab Combined with Fludarabine for Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (CLL). (2007) (5)
- PML-RARα isoform at diagnosis is associated with disease-free survival (DFS) in patients enrolled in the intergroup trial (C-9710) for treatment of acute promyelocytic leukemia (APL). (2006) (4)
- Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL (2021) (4)
- Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients (2022) (4)
- CGG‐repeat polymorphism of the BCR gene rules out predisposing alleles leading to the philadelphia chromosome (1994) (4)
- A phase II study of voreloxin as single agent therapy for elderly patients (pts) with newly diagnosed acute myeloid leukemia (AML). (2009) (4)
- Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the Global Phase 3 INO-VATE Trial: Efficacy and Safety By Baseline CD22 Expression Level (2017) (4)
- Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia (2021) (4)
- A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy. (1995) (4)
- Alemtuzumab Reduces Chronic Graft Versus Host Disease (cGVHD) and Treatment Related Mortality (TRM) after Reduced Intensity Conditioning for AML and MDS. (2007) (4)
- Posttransplant immunotherapy with a GM-CSF-based tumor vaccine following autologous stem cell transplant (ASCT) for acute myeloid leukemia (AML). (2004) (4)
- Prognostic significance of initial clinical and molecular genetic features of acute promyelocytic leukemia (APL): Results from the North American Intergroup Trial, C9710 (2007) (4)
- Actinomycosis presenting as an oral ulcer in a neutropenic patient. (2002) (4)
- Role of Remission Status and Prior Transplant in Optimizing Survival Outcomes Following Allogeneic Hematopoietic Stem Transplantation (HSCT) in Patients Who Received Inotuzumab Ozogamicin (INO) for Relapsed / Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) (2017) (4)
- Substance use, psychological distress, and quality of life (QOL) in adolescent and young adult (AYA) cancer patients with hematologic malignancies in early survivorship. (2016) (4)
- Abstract CT321: First results of a 10-day regimen of SGI-110 (guadecitabine), a second generation hypomethylating agent (HMA) in previously untreated elderly AML who are not candidates for intensive chemotherapy (2015) (4)
- Amino acid stress response genes promote L-asparaginase resistance in pediatric acute lymphoblastic leukemia (2021) (4)
- A Phase 2 Clinical Trial of AP23573, an mTOR Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies. (2005) (4)
- CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma (2019) (4)
- Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young Adults with Ph-Negative Acute Lymphoblastic Leukemia in First Complete Remission: Comparison of CALGB 10403 to Patients Reported to t (2019) (4)
- Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Advanced Hematologic Malignancies: Unexpected Renal Toxicity (2009) (4)
- Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin (2020) (4)
- Haplo+cord transplantation: Neutrophil and platelet recovery and long-term survival compared to double umbilical cord blood (UCB) transplantation--A case-cohort analysis. (2014) (4)
- A randomized phase II study of sapacitabine, an oral nucleoside analogue, in elderly patients with AML previously untreated or in first relapse or previously treated MDS. (2016) (4)
- A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. (2020) (4)
- Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative (2022) (4)
- Phase 2 Study of Oblimersen Sodium (G3139; Bcl-2 Antisense; Genasense®) Plus Gemtuzumab Ozogamcin (Mylotarg®) in Elderly Patients with Relapsed Acute Myeloid Leukemia (AML). (2004) (4)
- CD5+ Immunophenotype in the Bone Marrow but Not in the Peripheral Blood in a Patient with Hairy Cell Leukemia (2000) (3)
- Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories (2019) (3)
- Phase II trial of decitabine in myelofibrosis with myeloid metaplasia (2007) (3)
- Marqibo® (vincristine sulfate liposomes injection; VSLI) Optimizes the Dosing, Delivery, and Pharmacokinetic (PK) Profile of Vincristine Sulfate (VCR) In Adults with Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL) (2010) (3)
- A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia. (2015) (3)
- A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT (2022) (3)
- Challenges for Conducting Clinical Trials Evaluating Maintenance Chemotherapy In Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study (2010) (3)
- A phase I and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor belinostat (BEL) plus azacitidine (AZC) in advanced myeloid malignancies. (2011) (3)
- Geriatric Assessment (GA) May Identify Vulnerable Older Allogeneic Hematopoietic Cell Transplantation (HCT) Recipients (2009) (3)
- TP53 Aberrations By FISH in CLL and Complex Karyotype at Transformation Predict for Worse Outcome in Diffuse Large B-Cell Lymphoma - Richter Transformation: A Single Institution Series of 75 DLBCL-RT Cases (2018) (3)
- Outcomes of IDH-Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors (2019) (3)
- Combination of Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML) Is Feasible and Tolerable (2016) (3)
- CD52 Expression in Adult Acute Lymphoblastic Leukemia (ALL): Quantitative Flow Cytometry Provides New Insights. (2006) (3)
- Updates in the Management of Relapsed and Refractory Acute Lymphoblastic Leukemia: An Urgent Plea for New Treatments Is Being Answered! (2022) (3)
- Geriatric Assessment (GA) to Predict Survival in Older Allogeneic Hematopoietic Cell Transplantation (HCT) Recipients (2014) (3)
- Qualitative Study of Factors That Influence Treatment Decision-Making Among Community Oncologists and Older Patients with Acute Myeloid Leukemia (2018) (3)
- Optimizing use of L-asparaginase-based treatment of adults with acute lymphoblastic leukemia. (2021) (3)
- Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master Trial (2019) (3)
- Phase 1 Study of Weekly Vincristine Sulfate (VCR) Liposomes Injection (VSLI, Marqibo™) Plus Dexamethasone in Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) (2008) (3)
- A Double Blind Placebo-Controlled Randomized Phase III Study of High Dose Continuous Infusion Cytosine Arabinoside (araC) with or without Cloretazine® in Patients with First Relapse of Acute Myeloid Leukemia (AML). (2006) (3)
- Chapter 66 – Acute Lymphoblastic Leukemia in Adults (2018) (3)
- A Phase 1 Study of XmAb18968, a CD3-CD38 Bispecific Antibody for the Treatment of Patients with Relapsed/Refractory Acute Leukemia and T Cell Lymphoblastic Lymphoma (2021) (3)
- A double blind placebo-controlled randomized phase III study of high dose continuous infusion cytosine arabinoside (araC) with or without VNP40101M in patients (pts) with first relapse of acute myeloid leukemia (AML) (2008) (3)
- Eradication of Minimal Residual Disease during Treatment of Mantle Cell Lymphoma: CALGB 59909. (2004) (2)
- Inotuzumab Ozogamicin Versus Standard of Care for Relapsed/Refractory Acute Lymphoblastic Leukemia in the Phase 3 Randomized INO-Vate Trial: Outcomes By Salvage Treatment Phase (2016) (2)
- Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response (2019) (2)
- Symptom burdens and coping strategies in adolescent and young adult (AYA) cancer survivors with hematologic malignancies. (2016) (2)
- CD5+, CD11c+, CD20+ hairy cell leukemia. (1991) (2)
- Abl Kinase Domain Mutations Leading to Relapse of Ph+ Acute Lymphoblastic Leukemia (ALL) Occur Commonly and Can Be Detected At Initial Diagnosis: Molecular Results From CALGB 10001 (2011) (2)
- Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation (2019) (2)
- Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults. (2020) (2)
- New Approaches to Treating Challenging Subtypes of ALL in AYA Patients (2020) (2)
- Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia (2005) (2)
- Looking toward the future: novel strategies based on molecular pathogenesis of acute lymphoblastic leukemia. (2009) (2)
- Alemtuzumab-Containing Allogeneic Hematopoietic Cell Transplant (HCT) for Relapsed Lymphomas: Prognostic Factors and Outcome. (2009) (2)
- 2193 (2017) (2)
- Preliminary Results of Combined Haploidentical-Cord Blood Transplantation for Patients Lacking HLA Identical Donors (2008) (2)
- Sequential imatinib and chemotherapy yield reverse-transcriptase polymerase chain reaction (RT-PCR)-negative peripheral stem cell collections in Philadelphia (Ph) chromosome positive acute lymphoblastic leukemia (ALL)-Preliminary results of CALGB 10001. (2006) (2)
- Integration and feasibility of symptom burden assessment and early palliative care into an adolescent and young adult leukemia clinic. (2021) (2)
- A Phase 1b, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) with Vincristine and Dexamethasone in Adult Subjects with Relapsed or Refractory Acute Lymphoid Leukemia (ALL) (2015) (2)
- Suffering Before The Cure: Evaluation Of Psychological Morbidities In Adolescents and Young Adults With Hematologic Malignancies In Early Survivorship (2013) (2)
- Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (2022) (2)
- Philadelphia chromosome‐like acute lymphocytic leukemia: Perspectives on diagnosis (2019) (2)
- 947OCOMPARISON OF EFFICACY AND SAFETY OF 5-DAY AND 10-DAY SCHEDULES OF SGI-110, A NOVEL SUBCUTANEOUS (SC) HYPOMETHYLATING AGENT (HMA), IN THE TREATMENT OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML). (2014) (2)
- Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best Achieved with Adequate Treatment Duration (2019) (2)
- Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance) (2013) (2)
- KTE-C19, an Anti-CD19 Chimeric Antigen an Anti-CD19 Chimeric Antigen Receptor (CAR) T cell Therapy in Adult Patients (Pts) With Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) in the ZUMA-3 Trial: Preliminary Results of Novel Safety Interventions (2017) (2)
- Inotuzumab ozogamicin (InO) treatment in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): Analysis from INO-VATE by bone marrow blast percentage (BMB%). (2018) (2)
- Safety and Efficacy of Marqibo (Vincristine Sulfate Liposomes Injection, OPTISOME™) in for the Treatment of Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL). (2007) (2)
- Correction: Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR (2021) (2)
- High Dose Cytarabine (HiDAC) and Mitoxantrone (MITO) Is An Effective Induction Therapy for High-Risk Acute Myeloid Leukemia (AML). (2009) (2)
- Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia (2022) (2)
- Pivotal Phase 2 Study of Weekly Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®) in Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Progressing Following Two Anti-leukemia Treatment Lines. (2009) (2)
- Pre-treatment C-reactive Protein (CRP) is a Predictor for Allogeneic Hematopoietic Cell Transplantation Outcomes (2009) (2)
- Ganciclovir and high-dose valacyclovir reduce cytomegalovirus reactivation in patients receiving allogeneic stem cell transplantation with Campath-1H–based conditioning regimens (2005) (2)
- The Role of Structural Violence in Acute Myeloid Leukemia Outcomes (2020) (2)
- A multi‐institutional comparison of mitoxantrone, etoposide, and cytarabine vs high‐dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia (2020) (2)
- Approaches to treatment for acute lymphoblastic leukemia in adolescents and young adults (2008) (2)
- OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia (2021) (2)
- Biomarkers To Predict Outcome after Allogeneic Hematopoietic Cell Transplant (HCT). (2007) (2)
- Role of Remission Status and Prior Transplant in Optimizing Survival Outcomes Following Allogeneic Hematopoietic Stem Transplantation (HSCT) in Patients Who Received Inotuzumab Ozogamicin for Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) (2018) (2)
- Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation (2018) (2)
- Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial (2020) (2)
- Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome (2020) (2)
- Minimal Residual Disease (MRD) and Risk of Relapse in Acute Promyelocytic Leukemia (APL): Insights from the North American Intergroup Phase III Trial C9710. (2006) (2)
- A phase 1, open-label, dose-escalation, multicenter study to evaluate the tolerability, safety, pharmacokinetics, and activity of ADCT-301 in patients with relapsed or refractory CD25-positive acute myeloid leukemia. (2016) (2)
- Clinical, pharmacokinetic (PK), and pharmacodynamic findings from a phase I trial of an Eg5 inhibitor (AZD4877) in patients with refractory acute myeloid leukemia (AML). (2016) (2)
- Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation (Hct) in Patients with Advanced Hematologic Malignancies: A Phase I–II Study (2008) (1)
- D-dimer and risk for thrombosis in adults with newly diagnosed acute lymphoblastic leukemia (2022) (1)
- Prognostic significance of WT-1 levels in patients with myelodysplastic syndrome and leukemia after reduced-intensity allogeneic transplantation. (2006) (1)
- Early Estimates of Safety for Alemtuzumab Combined with Fludarabine for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia: Phase II Multicenter Study. (2006) (1)
- Plasma Vincristine Levels Are 100-Fold Higher with Marqibo® (Vincristine Sulfate LIPOSOME Injection) in Place of Standard Vincristine in Combination Chemotherapy of Patients ≥ 60 Years Old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) (2015) (1)
- hase II Study of Autologous Transplantation with nterleukin-2 – Incubated Peripheral Blood Stem Cells nd Posttransplantation Interleukin-2 in Relapsed r Refractory Non-Hodgkin Lymphoma (2004) (1)
- Thrombosis in ALL: a risk without clear mitigation. (2020) (1)
- Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study (2023) (1)
- Preface: acute lymphoblastic leukemia--quo vadis? (2009) (1)
- Phase I Study of XK469R (NSC 698215), a Quinoxaline Phenoxypropionic Acid Derivative, in Patients with Refractory Hematological Malignancies. (2006) (1)
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Entospletinib in Combination with Intensive Induction and Consolidation Chemotherapy in Adults with Newly Diagnosed N ucleophosmin 1-mutated Acute Myeloid Leukemia (2021) (1)
- Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia (2022) (1)
- Asparaginase Induced Liver Enzyme Elevation Is More Prevalent in Hispanics Children with ALL and in Patients with SOD2 rs4880 CC Genotype (2021) (1)
- Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at Enrolling Institutions Compared to Central Laboratory Results in the Beat AML Master Trial (2019) (1)
- Effect of Young Age on Outcomes in Pediatric Acute Promyelocytic Leukemia (APL): North American Intergroup Study CALGB 9710 (Alliance) (2014) (1)
- Low incidence of hepatic veno-occlusive disease (VOD) in patients with B-cell acute lymphoblastic leukemia (B-ALL) treated with inotuzumab ozogamicin (INO) followed by allogeneic stem cell transplantation (allo-SCT). (2021) (1)
- Supplementary Appendix for "Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia" (2014) (1)
- The Outcomes of Second Allogeneic Stem Cell Transplantation for Disease Relapse after T Cell Depleted Allogeneic Stem Cell Transplantation: A Single Center Experience-University of Chicago (2014) (1)
- Access and Referral Barriers to Autologous and Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Cancer: A Systematic Review with a Specific Focus on Geriatric Population (2018) (1)
- Pharmacokinetics and assessment of renal toxicity of a clofarabine (Clo), melphalan (Mel), and alemtuzumab (Alm) conditioning regimen. (2010) (1)
- WT1 Peptide Vaccine Is Able to Induce WT1-Specifc Immune Response with TCR Clonal Enrichment to Control Minimal Residual Disease in Patients with Myeloid Leukemia (2016) (1)
- A Phase II Prospective Feasibility Study of Clofarabine Cytoreduction Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Relapsed or Refractory Acute Leukemias and Advanced Myelodysplastic Syndromes (2011) (1)
- Comparison Of Deep Sequencing and Allele-Specific Oligonucleotide PCR Methods For MRD Quantitation In Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma: CALGB 10403 and CALGB 59909 (Alliance) (2013) (1)
- Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia (2018) (1)
- Abstract 952: Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia (2014) (1)
- A phase 4 study to evaluate outpatient blinatumomab in patients with minimal/measurable residual disease (MRD) positivity (+) of B-cell precursor acute lymphoblastic leukemia (BCP-ALL). (2021) (1)
- Dose-Escalation Study of Azacitidine Followed By High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in High-Risk Acute Myeloid Leukemia (AML) (2015) (1)
- Low Incidence of TALl Gene Rearrangements in Adult Acute Lymphoblastic Leukemia : A Cancer and Leukemia (2005) (1)
- Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 302 Patients with Relapsed or Refractory (r/r) Acute Myeloid Leukemia after Intensive Chemotherapy (ASTRAL-2 Study) (2021) (1)
- Open-label, dose-escalation, phase 1 study of venetoclax in combination with navitoclax and chemotherapy in patients with relapsed acute lymphoblastic leukemia. (2018) (1)
- Expression of an Oncogenic ERG isoform Characterizes a Distinct Subtype of B-Progenitor Acute Lymphoblastic Leukemia (2015) (1)
- Extensive safety profile of inotuzumab ozogamicin (InO) in relapsed/refractory acute lymphoblastic leukemia (ALL) patients enrolled in the phase 3 INO-VATE trial. (2018) (1)
- D-Dimer As a Predictor of Thrombotic Events during Early Acute Lymphoblastic Leukemia Therapy (2020) (1)
- Frequent PML-RAR α Mutations in Relapse Patients on Acute Promyelocytic Leukemia (APL) Intergroup Phase III Trial C9710. (2006) (1)
- Efficacy and tolerability of a modified pediatric‐inspired intensive regimen for acute lymphoblastic leukemia in older adults (2021) (1)
- Response: Disparity in outcome of young adults with ALL (2009) (1)
- Prognostic and Biologic Significance of Long Non-Coding RNA (lncRNA) Profiling in Cytogenetically Abnormal Acute Myeloid Leukemia (CA-AML) (2018) (1)
- Fludarabine Melphalan and Alemtuzumab (Campath) Conditioning for Pts with High Risk Myeloid Malignancies. High Cure Rate for Pts with Low Leukemia Burden. (2004) (1)
- Neurocysticercosis Coincident with Acute Myeloid Leukemia: A Case Report. (1991) (1)
- Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia (2019) (1)
- More or Less? Impact of Dose Number on Outcomes of Patients with Acute Lymphoblastic Leukemia Treated with Inotuzumab Ozogamicin (2019) (1)
- A phase II study of the tolerability and activity of weekly vincristine sulfate liposomes injection (VSLI) in adults with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second relapse or progressing following two antileukemia treatment lines. (2016) (1)
- Who Participates in an Adult Cooperative Group Trial for Adolescent and Young Adults (AYAs)? Baseline Demographic and Psychosocial Characteristics of AYAs Enrolled On Intergroup Trial C10403 for Acute Lymphoblastic Leukemia (ALL) (2012) (1)
- Abstract 819: High response rates with entospletinib in patients with t(v;11q23.3);KMT2Arearranged acute myeloid leukemia and acute lymphoblastic leukemia (2018) (1)
- Pharmacokinetic Results from a Phase 1 Study of a Multi-Targeted Tyrosine Kinase Inhibitor, ABT-869, in Patients with Refractory or Relapsed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) (2008) (1)
- Inotuzumab Ozogamicin (InO) for Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) in the Global Phase 3 INO-VATE Trial: Efficacy By MLL Status (2017) (1)
- Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (NCI9706 protocol; REMAIN Trial) (2022) (1)
- DNA Demethylation Activity Over Time and Safety Of 3 Different Dose-Escalation Regimens Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In The Treatment Of Relapsed/Refractory Patients With MDS and AML (2013) (1)
- Clinical trials in adult AML. (2009) (1)
- Is it time to use minimal residual disease to stratify post-remission treatment for acute myeloid leukemia? (2015) (1)
- *701 Detection of Minimal Residual Disease Following Induction Immunochemotherapy Predicts Progression Free Survival in Mantle Cell Lymphoma: Final Results of CALGB 59909 (2011) (1)
- Use of Chromosomal Microarray Analysis (CMA) to Identify Targetable Mutations in Acute Lymphoblastic Leukemia (2014) (1)
- Molecular Characterization of Adult Acute Lymphoblastic Leukemia Identifies a Subgroup with Myeloid Mutations and Pre-Existing Clonal Hematopoiesis (2022) (1)
- A Multi-Institution Comparison of Mitoxantrone, Etoposide and Cytarabine (MEC) Vs High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia (2018) (1)
- Anti-Angiogenic Effects of Sorafenib in Relapsed Chronic Lymphocytic Leukemia: Correlative Studies of a Phase 2 Clinical Trial. (2007) (1)
- Primary ovarian insufficiency secondary to chemotherapy with inotuzumab ozogamicin and other agents (2022) (1)
- MUC4 expression by immunohistochemistry is a specific marker for BCR-ABL1+ and BCR-ABL1-like B-lymphoblastic leukemia (2022) (1)
- Stem Cell Transplantation for a Highly Sensitized Patient (1999) (1)
- Should immunologic strategies be incorporated into frontline ALL therapy? (2018) (1)
- Reduced Intensity Conditioning with Combined Haploidentical and Cord Blood Transplantation Results in Rapid Engraftment and Durable Remissions in Hematological Malignancies (2011) (1)
- PULMONARY VASCULAR TOXICITY WITH TYROSINE KINASE INHIBITOR THERAPY: A RARE CASE IN A CHRONIC MYELOID LEUKEMIA PATIENT (2022) (1)
- Characterization of Survival Outcomes and Clinical and Molecular Modulators in Adult Patients with Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) Treated with Hidac Consolidation: An Alliance Legacy Study (2022) (0)
- A Phase 3 Study of CPX‐351 versus Conventional 7+3 Cytarabine and Daunorubicin: Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia with Excess of Blasts in Transformation (RAEB‐t): AML‐272 (2018) (0)
- The relationship of day 30 and day 100 donor chimerism to clinical outcomes following reduced-intensity allogeneic transplantation for hematologic malignancies (2006) (0)
- A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2-Mutant AML Patients: 3-Year Follow-up (2022) (0)
- Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. (2023) (0)
- Neurocognitive outcomes in survivors of early adolescent and young adult (eAYA) hematologic cancers from the Childhood Cancer Survivor Study (CCSS). (2021) (0)
- Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial. (2023) (0)
- Treatment-influenced associations of PML-RAR (cid:1) mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia (2012) (0)
- Single center experience treating adults with FLT3-mutated acute myeloid leukemia (AML). (2012) (0)
- Identifying trends for high symptom burden across the care continuum in adolescents and young adults (AYA) with hematologic malignancies. (2022) (0)
- Chromatin Accessibility Landscapes of B-Cell Acute Lymphoblastic Leukemia Identify Extensive Epigenomic Reprogramming and Heterogeneity Among Subtypes (2022) (0)
- PS951 MORE OR LESS? IMPACT OF DOSE NUMBER ON OUTCOMES OF PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH INOTUZUMAB OZOGAMICIN (2019) (0)
- A randomized phase II trial of maintenance versus consolidation bortezomib therapy following aggressive chemo-immunotherapy and autologous stem cell transplant for previously untreated mantle cell lymphoma. (2010) (0)
- Management of Hematologic Malignancies: Treatment of acute lymphoblastic leukemia (ALL) in adults (2010) (0)
- Biological Study of MG 98 , an Oligodeoxynucleotide Antisense to DNAMethyltransferase 1 , in Patients with High-RiskMyelodysplasia andAcuteMyeloid Leukemia (2008) (0)
- Comparison of chemotherapy dose intensity for AYAs on COG AALL1131 versus CALGB 10403. (2020) (0)
- Hispanic ethnicity and the rs4880 variant in SOD2 are associated with elevated liver enzymes and bilirubin levels in children receiving asparaginase-containing chemotherapy for acute lymphoblastic leukemia (2022) (0)
- A Comparison of Outcomes Between Adolescents and Young Adults (AYA) and Children with Acute Promyelocytic Leukemia (APL): North American Intergroup Study CALGB 9710 (Alliance) (2014) (0)
- Sex-Associated Differences in Frequencies and Outcome Prognostication of Recurrent Molecular Features in Adults with Acute Myeloid Leukemia (AML) (AMLCG, CALGB [Alliance]) (2022) (0)
- TARGETING RNA EPIGENETICS TO PREDICT AND OVERCOME DRUG RESISTANCE IN MDS AND AML (2023) (0)
- ALL-269 Safety and Pharmacokinetics of Calaspargase Pegol in Adults With Newly Diagnosed Philadelphia-Negative Acute Lymphoblastic Leukemia: A Phase 2/3 Study. (2022) (0)
- Epigenomic mapping in B-cell acute lymphoblastic leukemia identifies transcriptional regulators and noncoding variants promoting distinct chromatin architectures (2023) (0)
- Editorial. (2020) (0)
- How I Treat How I treat acute lymphoblastic leukemia in older adolescents and young adults (2015) (0)
- Outcomes of Older Adults With AML Treated in Community Versus Academic Centers: An Analysis of Alliance Trials. (2023) (0)
- Measures of Structural Racism Predict ICU Admission Following Intensive Chemotherapy for AML (2022) (0)
- Recent progress in the treatment of acute lymphoblastic leukemia (2009) (0)
- Abstract 4381: High efficacy of T-LAK cell-originated protein kinase inhibitor in acute myeloid leukemia with FLT3-ITD mutation (2015) (0)
- Management of myelodysplastic syndromes (1996) (0)
- Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation (2022) (0)
- PS940 COMBINATION BCL-2 INHIBITOR THERAPY WITH VENETOCLAX AND NAVITOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOBLASTIC LYMPHOMA (2019) (0)
- Race-Ethnic Enrollment Disparities over 15 Years of Alliance/CALGB Acute Myeloid Leukemia Clinical Trials, Biobanks, and Correlative Science Protocols (2021) (0)
- Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy (2018) (0)
- The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study (2022) (0)
- Expanding Use of a Modified Pediatric Intensive Regimen for Acute Lymphoblastic Leukemia (ALL) into an Older Adult Population: Feasibility and Efficacy Results (2020) (0)
- The Influence of the Age of the Bone Marrow Microenvironment on Leukaemia Progression (2019) (0)
- Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates. (2022) (0)
- New Cytogenetic Abnormalities Are Frequent in AML and MDS Relapsing after Allogeneic Hematopoietic Cell Transplantation (HCT). (2006) (0)
- Can We Do Better In Management Of Neutropenic Fever In Hematological Patients (2010) (0)
- MPN-288: Molecular Characteristics of IDH2-Mutated, Philadelphia Chromosome-Negative, Advanced-Phase Myeloproliferative Neoplasms Treated with Enasidenib (2020) (0)
- Loss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T lymphocyte acute lymphoblastic leukemia (2023) (0)
- Comprar Recent Progress in the Treatment of Acute Lymphoblastic Leukemia, An Issue of Hematology/Oncology Clinics of North America | Wendy Stock | 9781437712278 | Saunders (2010) (0)
- Clinical Utility of DNA Arrays in Detecting Chromosomal Aberrations Associated with High-Risk Philadelphia-Like Acute Lymphoblastic Leukemia (2014) (0)
- P525: PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF ENTOSPLETINIB ADDED TO INTENSIVE INDUCTION AND CONSOLIDATION CHEMOTHERAPY IN NEWLY DIAGNOSED NPM1-MUTATED AML (2022) (0)
- Screening for clonal hematopoiesis as a predictive marker for development of t-AML following adjuvant therapy for breast cancer (S0012) (2007) (0)
- Subject Index Vol. 103, 2000 (2000) (0)
- Inotuzumab ozogamicin (InO) treatment in patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL): Outcomes of patients treated in salvage one with a long duration of first remission. (2019) (0)
- 223: C-reactive protein (CRP) may predict transplant-related mortality after allogeneic hematopoietic cell transplant (HCT) (2007) (0)
- Pediatric regimens for adult acute lymphoblastic leukemia. (2009) (0)
- 1007PDPreliminary results of novel safety interventions in adult patients (pts) with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) in the ZUMA-3 Trial (2017) (0)
- Combinations of Kinase Inhibitors May Be An Effective Therapeutic Strategy for Acute Myeloid Leukemia (AML) with MLL-AF9 Expression. (2009) (0)
- Clonal Markers In Relapsed Acute Promyelocytic Leukemia (APL): Clinicopathological Associations and Relation to All-Trans Retinoic Acid (ATRA) Treatment on Intergroup Phase III Trial C9710. (2010) (0)
- Growth Inhibitory Function Of a Novel T-LAK Cell-Originated Protein Kinase Inhibitor On FLT3-ITD Positive Acute Myeloid Leukemia (AML) Cells (2013) (0)
- Novel drug targets in acute leukemia. (2015) (0)
- Poster: ALL-040 The Impact of Age-Related Clonal Hematopoiesis on Outcomes of Adults With Acute Lymphoblastic Leukemia (2022) (0)
- Mimetic Peptide to CDK Inhibitor p16 INK4a Induces Cell Death In Mantle Cell Lymphoma Cells: A New Strategy to Eradicate Minimal Residual Disease (2010) (0)
- 2193: Targeting MELK in acute lymphoblastic leukemia, new therapeutic approach (2017) (0)
- Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention (2022) (0)
- Clinical and Molecular Characteristics of Therapy-Related Acute Lymphoblastic Leukemia (2017) (0)
- Functional investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment (2023) (0)
- Abstract 3083: The genetic landscape of Ph-like acute lymphoblastic leukemia (2014) (0)
- Allogeneic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia (2003) (0)
- Abstract CT023: A phase I study of eryaspase (L-asparaginase encapsulated in red blood cells) in combination with induction and consolidation chemotherapy for adult patients (pts) with newly diagnosed acute lymphoblastic leukemia (ALL) (2018) (0)
- Amino acid stress response genes promote L-asparaginase resistance in pediatric acute lymphoblastic leukemia (2022) (0)
- 5hmC Gene Signature Predicts the Treatment Response to Azacitidine with High-Dose Cytarabine and Mitoxantrone in AML (2021) (0)
- A prospective feasibility study of clofarabine (CLO) cytoreduction prior to allogeneic stem cell transplant (HCT) conditioning for refractory leukemia and MDS. (2010) (0)
- Emerging Treatment Options in Adult Acute Myelogenous Leukemia (2013) (0)
- Minimal Residual Disease Studies in Acute Lymphoblastic Leukemia (2008) (0)
- Evaluation of a pre-transplant serum biomarker score for allogeneic hematopoietic stem cell transplant (HCT) and association with clinical factors. (2016) (0)
- 252Valacyclovir compared to acyclovir for cytomegalovirus prophylaxis in allogeneic stem cell transplants recipients (2003) (0)
- Characterization of Tcra and Tcrb Repertoires in Acute Myeloid Leukemia Patients before and after Combined Haploidentical and Umbilical Cord Blood Transplant (2014) (0)
- Treatment of Therapy-Related Myeloid Neoplasms with High-Dose Cytarabine/Mitoxantrone Followed by Hematopoietic Cell Transplantation (HCT). (2009) (0)
- Minimal Residual Disease in Adults with Advanced Relapsed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Treated with Marqibo® (vinCRIStine sulfate LIPOSOME injection) (2012) (0)
- Remission Status and Performance Status, but Not Cytogenetic Risk Group, Are Associated with Outcome After Reduced Intensity Conditioning (RIC) and Allogeneic Hematopoietic Cell Transplantation (HCT) for Therapy-Related Myeloid Neoplasms (t-MN): Results of the University of Chicago Experience. (2009) (0)
- Final Results from a Phase I Trial Combining Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML) (2018) (0)
- Structural and Social Barriers to Survival in Adolescent and Young Adult (AYA) Patients with Acute Myeloid Leukemia (AML) (2021) (0)
- Gilteritinib (GILT) Monotherapy with Addition of Decitabine (DEC) in Non-Responders in Older Newly Diagnosed (ND) FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Having High and Low Variant Allele Frequency (VAF): A Phase 2/1b Sub-Study of the Beat AML Master Trial (2021) (0)
- A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML) (2022) (0)
- Ivosidenib (IVO) in Combination with Azacitidine (AZA) in Newly Diagnosed (ND) Older Patients with IDH1 R132-Mutated Acute Myeloid Leukemia (AML) Induces High Response Rates: A Phase 2 Sub-Study of the Beat AML Master Trial (2021) (0)
- OP17 Arsenic trioxid improves survival in first line APL consolidation treatment: the NCI/CALGB study results (2007) (0)
- Management of Important Adverse Events Associated with Inotuzumab Ozogamicin in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia (2017) (0)
- Eltrombopag Is a Safe and Effective Agent to Treat Thrombocytopenia after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) (2023) (0)
- Frequency of target attainment and toxicity with reduced PEG-asparaginase (PEG) dosing in acute lymphoblastic leukemia (ALL). (2017) (0)
- Contents Vol. 103, 2000 (2000) (0)
- PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia (2019) (0)
- Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (2022) (0)
- Clinical and molecular response of AML harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors (2022) (0)
- Unrelated Donor (URD) Searches in African-Americans with Hematologic Malignancies: Paucity of HLA Identical Donors. (2007) (0)
- Enrollment Characteristics and Outcomes of Hispanic and Black AYA ALL Patients Enrolled on a U.S. Intergroup Clinical Trial: A Comparison of the CALGB 10403 (Alliance) Cohort with U.S. Population-Level Data (2021) (0)
- Title: How I Treat: Acute Lymphoblastic Leukemia in Older Adolescents and Young Adults (AYAs) Running Title: Treatment of ALL in Adolescents and Young Adults (AYAs) (2015) (0)
- Epigenetic Fine Mapping and Functional Dissection of Inherited Non-Coding Variation Impacting the Pharmacogenomics of Acute Lymphoblastic Leukemia Treatment (2022) (0)
- Outcome Prediction By the New 2022 European Leukemia Net (ELN) Genetic-Risk Classification for Adult Patients (Pts) with Acute Myeloid Leukemia (AML): An Alliance Study (2022) (0)
- Abstract CT027: Exploration of association of leukemic molecular profile with efficacy in patients (pts) with relapsed/refractory acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial (2022) (0)
- Comorbidity from Solid Tumor or Hematologic Malignancy Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) May Both Increase Non-Relapse Mortality (2016) (0)
- Efficacy and Safety of Inotuzumab Ozogamicin in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated in the INO-VATE Trial: Outcomes by Salvage-Treatment Phase (2019) (0)
- Counterpoint: Standard vs Investigational Agents as Upfront Treatment for High-Risk AML. (2017) (0)
- Alemtuzumab (Campath 1-H) Exposure Correlates with Risk of Chronic Graft vs Host Disease and CMV Viremia after Allogeneic Transplantation. (2005) (0)
- Incidence and Predictors of Respiratory Viral Infections By Multi-Plex PCR in Allogeneic Hematopoietic Cell Transplant (HCT) Recipients 50 Years and Older Including Geriatric Assessment (GA) (2014) (0)
- Inhibition of FLT3-ITD and Melk By Small Molecule Inhibitor OTS167 in FLT3 mutant Acute Myeloid Leukemia (AML) (2017) (0)
- OTS167 Inhibits FLT3 Expression in FLT3 Mutant Acute Myeloid Leukemia (2019) (0)
- Entospletinib (ENTO) and Decitabine (DEC) Combination Therapy in Older Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Patients with Mutant TP53 or Complex Karyotype Is Associated with Poor Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial (2021) (0)
- Mentorship Through Literature (2020) (0)
- Combination BCL-2 Inhibitor Therapy with Venetoclax and Navitoclax in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (2019) (0)
- Results of Phase I/II VMAT-TMI Dose Escalation Study Of Patients Undergoing Second Allogeneic Stem Cell Transplantation (2020) (0)
- Leukemic Relapse after Allogeneic Stem Cell Transplantation with a T-Cell Depleted Reduced Intensity Conditioning (RIST) Regimen. (2005) (0)
- Targeting Apoptosis with Novel BH3 Mimetics in T-Lineage Acute Lymphoblastic Leukemia (2022) (0)
- FLT3 Inhibitor Maintenance after Allogeneic Stem Cell Transplantation in FLT3-Mutated Acute Myeloid Leukemia (AML) Patients (2023) (0)
- CD5+, CD11C+, HAIRY CELL LEUKEMIA. RESPONSE (1991) (0)
- Molecular Landscape in Acute Myeloid Leukemia (AML) Patients (pts) from Mexico As an Initial Study to Identify Healthcare Disparities in Hispanic Populations: Alliance for Clinical Trials in Oncology [Alliance] (2022) (0)
- Age-Related Clonal Hematopoiesis Is a Precursor for Adult Acute Lymphoblastic Leukemia (2021) (0)
- ALL-040 The Impact of Age-Related Clonal Hematopoiesis on Outcomes of Adults With Acute Lymphoblastic Leukemia. (2022) (0)
- Phase 2 study of guadecitabine (SGI-110), a novel hypomethylating agent, in treatment-naïve patients with acute myeloid leukaemia who are not candidates for intensive chemotherapy (2018) (0)
- Regularized Mixture Cure Models Identify a Gene Signature That Improves Risk Stratification within the Favorable-Risk Group in 2017 European Leukemianet (ELN) Classification of Acute Myeloid Leukemia (Alliance 152010) (2022) (0)
- Influence of participant and reviewer characteristics in application scores for a hematology research training program. (2023) (0)
- Targeting Bone Marrow Lymphoid Niches In Acute Lymphoblastic Leukemia (2013) (0)
- 159: Feasibility of Clofarabine Cytoreduction before Initiation of Allogeneic Stem Cell Transplant Regimen During the Cytopenic Phase for Patients with Refractory Acute Myelogenous Leukemia (2008) (0)
- Acute Leukemia in Adults (2003) (0)
- expressing results transcripts and kinase domainBCR-ABLmethodology for detecting inhibitors : review and recommendations for harmonizing current Monitoring CML patients responding to treatment with tyrosine kinase (2006) (0)
- ALL-144: Oncogenic Deregulation of BCL11B in Lineage Ambiguous Leukemia (2021) (0)
- Il-2 plus g-csf as a mobilization regimen in advanced breast cancer patients receiving high dose chemotherapy: marked expansion of activated t and nk cells with enhanced cytolyt1c activity within the autograft, without compromise of the hematologic engraftment (1998) (0)
- Clinical and Molecular Response Assessment of AML Harboring Non-Canonical FLT3 p.N676K Driver Mutations to FLT3 Inhibitor Therapies (2022) (0)
- Late Mortality and Chronic Health Conditions in Long-term Survivors of Adolescent and Early Young Adult Cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study (2020) (0)
- Sequencing antigen‐targeting antibodies and cellular therapies in adults with relapsed/refractory B‐cell acute lymphoblastic leukemia (2023) (0)
- Intracellular Levels of Oblimersen Sodium and Target Downregulation Correlates to Clinical Activity of bcl-2 Antisense in Acute Myeoid Leukemia (AML). (2004) (0)
- Prospective Measurement of BK Virus Blood and Urine Levels, and Associations with Morbidity, in Recipients of Allogeneic Hematopoetic Stem Cell Transplants. (2007) (0)
- Self-reported positive impact of mentored clinical research training is associated with academic success in hematology. (2021) (0)
- Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia. (2023) (0)
- Predictors of Response and Survival in 206 AML Patients Treated with Guadecitabine in a Phase 2 Study (2017) (0)
- PS949 INOTUZUMAB OZOGAMICIN (INO) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL): OUTCOMES OF PATIENTS TREATED IN SALVAGE ONE WITH A LONG DURATION OF FIRST REMISSION (2019) (0)
- 649TiP A phase I/Ib study evaluating the safety, pharmacokinetics, and preliminary efficacy of LP-118 in subjects with relapsed or refractory haematological malignancies (2022) (0)
- Phase I Trial of Sphingosomal Vincristine (SV, Marqibo®) and Dexamethasone in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL). (2006) (0)
- Prior invasive fungal infection does not preclude successful allogeneic transplantation (2006) (0)
- Minimal residual disease: current status in leukemia. (2003) (0)
- Listen to Thy Patient: Poor Quality of Life (QoL) Reported by Older Adults Prior to Allogeneic Stem Cell Transplantation (allo-HCT) Is Independently Associated with Worse Transplant Outcomes (2012) (0)
- Outcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. (2022) (0)
- Genomic Integration of Adult and Pediatric Acute Myeloid Leukemia Reveals Age Dependent Risk Association (2022) (0)
- Frequency and Risk Factors of Cord Graft Failure (CGF) Following Reduced Intensity Conditioning Haplo-Cord Hematopoietic Stem Cell Transplantation (2014) (0)
- Randomized Phase 2 Study of Guadecitabine in Patients with HMA-Naive Higher Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) (2017) (0)
- Safety and Pharmacokinetics of Calaspargase Pegol in Adults with Newly Diagnosed Philadelphia-Negative ALL: A Phase 2/3 Study (2021) (0)
- Role of Racial, Demographic and Socioeconomic Disparities in Treatment Patterns and Outcomes in AML (2019) (0)
- PS950 EFFICACY AND SAFETY OF INOTUZUMAB OZOGAMICIN IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA TREATED IN THE INO-VATE TRIAL: OUTCOMES BY SALVAGE-TREATMENT PHASE (2019) (0)
- Distinct Genetic Pathways Define Leukemia Predisposition Versus Adaptive Clonal Hematopoiesis in Shwachman-Diamond Syndrome (2020) (0)
- Efficacy of Single-Agent Decitabine in Relapsed and Primary Refractory (rel/ref) Acute Myeloid Leukemia (AML) (2015) (0)
- Phase I Trial of a Novel Conditioning Regimen Utilizing Total Marrow Irradiation (TMI) with Fludarabine-Melphalan for Patients with Relapsed Hematologic Malignancies Undergoing Second Allogeneic Stem Cell Transplantation (Allo-SCT) (2020) (0)
- Association of clofarabine (Clo)-associated GFR decline (GFRd) with dose and AUC. (2012) (0)
- Erratum: Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia (Cancer (2013) 119 (90-8)) (2014) (0)
- Molecular and Clinical Features of FLT3 Juxtamembrane Domain Point Mutations (muts) in Acute Myeloid Leukemia (AML) (2022) (0)
- Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS (2019) (0)
- Higher Socioeconomic Status Is Associated with Improved Overall Survival in Adults with Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia: A Population Study (2018) (0)
- Feasibility of early withdrawal of immunosuppression (WOI) followed by dose escalation of prophylactic donor lymphocyte infusion (pDLI) after T-cell depleted (TCD) matched donor allogeneic hematopoietic cell transplantation (HCT). (2016) (0)
- Recurrent MEF2D Fusions Define A New Subtype of Acute Lymphoblastic Leukemia Associated with Older Age at Diagnosis and Poor Outcome (2016) (0)
- Abstract 4492: Characterization of the T-Cell receptor repertoire in patients with acute myeloid leukemia treated with 5-Azacytidine plus chemotherapy (2020) (0)
- Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Term Follow up from Phase 2 Study of 103 Patients (2019) (0)
- Subject Index Vol. 61, 1992 (1992) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Wendy Stock?
Wendy Stock is affiliated with the following schools:
